Fast-fashion recycling: how ‘the castoff capital of the world’ is making Indian factory workers sick

The GuardianTuesday, October 7, 2025 at 4:00:32 AM
Fast-fashion recycling: how ‘the castoff capital of the world’ is making Indian factory workers sick
In Panipat, known as the 'castoff capital of the world', alarming reports of lung disease, skin conditions, and cancer are emerging among factory workers involved in textile recycling. The city processes a staggering 1 million tonnes of textile waste annually, and the working conditions are dire, with air thick with harmful lint. This situation not only highlights the health risks faced by workers but also raises questions about the sustainability and ethics of fast fashion, making it a critical issue for consumers and policymakers alike.
— Curated by the World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Oncoinvent reports promising results for cancer treatment Radspherin
PositiveFinancial Markets
Oncoinvent has announced promising results for its cancer treatment, Radspherin, which could significantly improve patient outcomes. This development is crucial as it highlights advancements in cancer therapies, offering hope to patients and families affected by this disease.
Oncoinvent reports promising results for cancer treatment Radspherin
PositiveFinancial Markets
Oncoinvent has announced promising results for its cancer treatment, Radspherin, which could significantly improve patient outcomes. This development is crucial as it highlights advancements in cancer therapies, offering hope to patients and families affected by this disease.
Johnson & Johnson ordered to pay $966 million in talc cancer case after jury finds company liable
NegativeFinancial Markets
In a significant legal ruling, Johnson & Johnson has been ordered to pay $966 million after a jury found the company liable in a talc cancer case. This decision highlights the ongoing concerns surrounding the safety of talcum powder products and their potential link to cancer, affecting countless consumers and raising questions about corporate responsibility. The outcome of this case could set a precedent for future lawsuits and impact the company's reputation and financial standing.
Johnson & Johnson ordered to pay $966 million in talc cancer case after jury finds company liable
NegativeFinancial Markets
In a significant legal ruling, Johnson & Johnson has been ordered to pay $966 million after a jury found the company liable in a talc cancer case. This decision highlights the ongoing concerns surrounding the safety of talcum powder products and their potential link to cancer, affecting countless consumers and raising questions about corporate responsibility. The outcome of this case could set a precedent for future lawsuits and impact the company's reputation and financial standing.
Kazia Therapeutics signs deal for novel cancer immunotherapy asset
PositiveFinancial Markets
Kazia Therapeutics has signed a significant deal to acquire a novel cancer immunotherapy asset, marking a promising step forward in their mission to combat cancer. This partnership not only enhances Kazia's portfolio but also reflects the growing interest and investment in innovative cancer treatments. The deal is expected to accelerate the development of new therapies, potentially offering hope to patients and advancing the field of oncology.
Kazia Therapeutics signs deal for novel cancer immunotherapy asset
PositiveFinancial Markets
Kazia Therapeutics has signed a significant deal to acquire a novel cancer immunotherapy asset, marking a promising step forward in their mission to combat cancer. This partnership not only enhances Kazia's portfolio but also reflects the growing interest and investment in innovative cancer treatments. The deal is expected to accelerate the development of new therapies, potentially offering hope to patients and advancing the field of oncology.
Telomir-1 shows promise in reactivating tumor suppressor genes
PositiveFinancial Markets
Recent studies on telomir-1 have shown promising results in reactivating tumor suppressor genes, which could lead to new therapies for cancer treatment. This breakthrough is significant as it opens up potential avenues for combating various types of cancer, offering hope to patients and researchers alike.
Telomir-1 shows promise in reactivating tumor suppressor genes
PositiveFinancial Markets
Recent studies on telomir-1 have shown promising results in reactivating tumor suppressor genes, which could lead to new therapies for cancer treatment. This breakthrough is significant as it opens up potential avenues for combating various types of cancer, offering hope to patients and researchers alike.
Jefferies raises Nanobiotix stock price target to EUR21.00 on broad cancer potential
PositiveFinancial Markets
Jefferies has raised its price target for Nanobiotix to EUR 21.00, highlighting the company's broad potential in cancer treatment. This adjustment reflects growing confidence in Nanobiotix's innovative approaches to oncology, which could significantly impact patient care and the market. Investors and stakeholders should take note, as this could signal a promising future for the company and its contributions to cancer therapies.
Jefferies raises Nanobiotix stock price target to EUR21.00 on broad cancer potential
PositiveFinancial Markets
Jefferies has raised its price target for Nanobiotix to EUR 21.00, highlighting the company's broad potential in cancer treatment. This adjustment reflects growing confidence in Nanobiotix's innovative approaches to oncology, which could significantly impact patient care and the market. Investors and stakeholders should take note, as this could signal a promising future for the company and its contributions to cancer therapies.
Latest from Financial Markets
Mizuho lowers Shift4 Payments stock price target on international headwinds
NegativeFinancial Markets
Mizuho has lowered its stock price target for Shift4 Payments due to international headwinds affecting the company's performance. This adjustment reflects concerns about the challenges Shift4 may face in global markets, which could impact its growth and profitability. Investors should pay attention to these developments as they could influence the stock's future trajectory.
Select Medical stock price target raised by RBC Capital to $20 on regulatory relief
PositiveFinancial Markets
RBC Capital has raised its price target for Select Medical's stock to $20, citing recent regulatory relief as a key factor. This adjustment reflects growing confidence in the company's future performance and highlights the positive impact of regulatory changes on its operations. Investors may see this as a promising sign for Select Medical's growth potential.
Mizuho lowers Corteva stock price target to $78 on split announcement
NegativeFinancial Markets
Mizuho has lowered its price target for Corteva's stock to $78 following the company's announcement of a stock split. This adjustment reflects concerns about the potential impact of the split on investor confidence and market performance. Investors should pay attention to how this change might affect Corteva's stock in the coming months, as it could influence trading strategies and overall market sentiment.
Zenas Biopharma licenses three autoimmune candidates from InnoCare
PositiveFinancial Markets
Zenas Biopharma has successfully licensed three promising autoimmune candidates from InnoCare, marking a significant step forward in their development pipeline. This collaboration not only enhances Zenas's portfolio but also underscores the growing importance of innovative treatments in the autoimmune space. The partnership is expected to accelerate research and bring new therapies to patients in need, highlighting the potential for improved health outcomes.
Frontline stock gets Buy rating reaffirmation from BTIG on strong tanker market
PositiveFinancial Markets
Frontline stock has received a reaffirmed 'Buy' rating from BTIG, reflecting confidence in the company's performance amid a robust tanker market. This endorsement is significant as it highlights the potential for growth and profitability in the shipping sector, which is currently benefiting from increased demand and favorable market conditions.
Kitagawa, Robson and Yaghi win 2025 Nobel Prize in Chemistry
PositiveFinancial Markets
In a remarkable achievement, Yoshio Kitagawa, David Robson, and Omar Yaghi have been awarded the 2025 Nobel Prize in Chemistry for their groundbreaking work in the field of porous materials. This recognition not only highlights their innovative contributions but also underscores the importance of chemistry in addressing global challenges such as energy storage and environmental sustainability. Their research paves the way for future advancements that could significantly impact various industries and improve our daily lives.